The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

According to Vertex Pharmaceuticals, approximately 300 additional ... 6 years and older with at least 1 qualifying non-F508del Trikafta-responsive mutation and with no exclusionary mutation.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

(You can read the full research report on Toyota Motor here >>>) Vertex Pharmaceuticals' shares ... driven by higher sales of Trikafta/Kaftrio in younger age groups. Its one-shot gene therapy ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

Vertex Pharmaceuticals' suzetrigine is an investigational ... Alyftrek is yet another improvement from its latest gem, Trikafta. Among other things, Alyftrek is just as effective despite its ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... and lower sweat chloride levels than TRIKAFTA, is another step in achieving this goal.” “In Phase 3 clinical trials, across a broad range ...